Idiopathic pulmonary fibrosis and pirfenidone

European Respiratory Journal

Volumn 35, Issue 4, 2010, Pages 728-729

  Collard, H R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PIRFENIDONE; PLACEBO;

ANOREXIA; CLINICAL TRIAL; DRUG MEGADOSE; DYSPNEA; EDITORIAL; EXERCISE TEST; FIBROSING ALVEOLITIS; HUMAN; LOW DRUG DOSE; LUNG FUNCTION; PHOTOSENSITIVITY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; TREATMENT OUTCOME; VITAL CAPACITY;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; PYRIDONES; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 77951171086     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00006610     Document Type: Editorial

References (14)

1. Demedts M, Behr J, Buhl R, et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med. 2005; 353: 2229-2242. (Pubitemid 41697286)
2. King TE Jr, Albera C, Bradford WZ, et al. Effect of interferon c-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial. Lancet 2009; 374: 222-228.
3. King TE Jr, Behr J, Brown KK, et al. BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2008; 177: 75-81.
4. Raghu G, Brown KK, Bradford WZ, et al. A placebo-controlled trial of interferon c-1b in patients with idiopathic pulmonary fibrosis. N Engl J Med 2004; 350: 125-133. (Pubitemid 38056223)
5. Raghu G, Brown KK, Costabel U, et al. Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial. Am J Respir Crit Care Med 2008; 178: 948-955.
6. Taniguchi H, Ebina M, Kondoh Y, et al. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J 2010; 35: 821-829.
7. Raghu G, Johnson WC, Lockhart D, et al. Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of a prospective, open-label Phase II study. Am J Respir Crit Care Med 1999; 159: 1061-1069. (Pubitemid 29202536)
8. O'Neill RT. Secondary endpoints cannot be validly analyzed if the primary endpoint does not demonstrate clear statistical significance. Control Clin Trials 1997; 18: 550-556. (Pubitemid 27520843)
9. Collard HR, King TE Jr, Bartelson BB, et al. Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2003; 168: 538-542.
10. King TE Jr, Safrin S, Starko KM, et al. Analyses of efficacy end points in a controlled trial of interferon-c-1b for idiopathic pulmonary fibrosis. Chest 2005; 127: 171-177. (Pubitemid 41724573)
11. US Dept of Health and Human Services Food and Drug Administration, CBER, CDER, CDRH. Guidance for Clinical Trial Sponsors: Establishment and Operation of Clinical Trial Data Monitoring Committees. 2006 Available from: www.fda.gov/downloads/RegulatoryInformation/Guidances/UCM127073.pdf Date last accessed: December 29, 2009.
12. Liu G, Gould AL. Comparison of alternative strategies for analysis of longitudinal trials with dropouts. J Biopharm Stat 2002; 12: 207-226. (Pubitemid 35205022)
13. Swigris JJ, Brown KK, Behr J, et al. The SF-36 and SGRQ: validity and first look at minimum important differences in IPF. Respir Med 2009; [Epub ahead of print DOI: 10.1016/j.med.2009.09.006].
14. InterMune. Investor Relations. Available from: http://phx. corporate-ir.net/phoenix.zhtml?c5100067&p5irol-IRHome Date last accessed: December 29, 2009.